Arkolith/Insider Trading/XFOR/Form 4

DiBiase Mary

Chief Operating OfficerX4 Pharmaceuticals, Inc (XFOR) · full profile →Form 4 · filed Nov 3, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$49K
Net Open-Market Flow
-$49K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 1, 2023Sell(S)68K$0.73$49K311K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-23-036757) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML